Emergent BioSolutions Confirms Approximately $400 million in Orders in 2024 & 2025 to Support Smallpox and Mpox Preparedness Efforts

Core Viewpoint - Emergent BioSolutions Inc. has secured approximately $400 million in orders for its vaccinia, smallpox, and mpox product portfolio for 2024 and 2025, highlighting its role in public health preparedness against viral threats [1][2] Group 1: Financial and Contractual Highlights - The company has received a U.S. government contract modification for ACAM2000® and VIGIV, with nearly $210 million in customer orders delivered in 2024 [1] - Emergent is confirmed to deliver an additional $185+ million in ACAM2000® and VIGIV orders for the remainder of 2024 and into 2025 [1] Group 2: Regulatory and Health Initiatives - The U.S. FDA approved an update for ACAM2000® to include prevention of mpox disease for high-risk individuals, expanding its use beyond smallpox [2] - Emergent submitted an Expression of Interest for ACAM2000® to the WHO for Emergency Use Listing (EUL) assessment, responding to the WHO's call for mpox vaccine manufacturers [3] Group 3: Community Support and Contributions - Emergent has donated 50,000 doses of ACAM2000® for potential deployment in affected countries in Africa, demonstrating its commitment to addressing the mpox outbreak [4]